mRNA Vaccines And Therapeutics Market, By Treatment Type, By Type, By Application, By End User, By Country, and By Region -Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033

Description

mRNA Vaccines And Therapeutics Market size was valued at US$2,980.76 Million in 2025, expanding at a CAGR of 30.6% from 2026 to 2033.

mRNA Vaccines And Therapeutics refer to a class of advanced biotechnology solutions that use messenger RNA to instruct cells to produce specific proteins for disease prevention or treatment. This approach enables the body's immune system to recognize and respond to targeted pathogens or abnormal cells. mRNA-based platforms utilize genetic instructions to trigger controlled protein production, supporting the development of vaccines and therapeutic applications for infectious diseases, cancer, and other medical conditions. These solutions offer advantages such as rapid development, precise targeting, and flexible design. By enhancing immune response and enabling faster innovation, mRNA Vaccines And Therapeutics contribute to the advancement of modern medicine and next-generation healthcare treatments.

mRNA Vaccines And Therapeutics Market- Market Dynamics

Increasing Prevalence Of Chronic Diseases

Increasing prevalence of chronic diseases refers to the growing number of individuals affected by long-term medical conditions such as cancer, cardiovascular diseases, and autoimmune disorders worldwide. This trend is driven by factors including aging populations, lifestyle changes, and environmental influences, which are placing greater pressure on healthcare systems. In the context of mRNA Vaccines And Therapeutics, the rising burden of chronic diseases is encouraging the development of innovative treatment approaches that utilize mRNA technology to target specific disease pathways. mRNA platforms support personalized targeted therapies while rising chronic disease prevalence accelerates research and investment in advanced biotechnology treatments. The increasing prevalence of chronic diseases drives clinical research and therapeutic development, strengthening the demand for mRNA Vaccines And Therapeutics in modern healthcare.For instance, in November 2025, according to the Organisation for Economic Co-operation and Development (OECD), chronic conditions such as cardiovascular diseases, cancer, respiratory diseases, and diabetes remain major health burdens across OECD countries. The report highlights that around 8.6% of the adult population was living with diabetes in 2022, and over one-third of people aged 16 and above reported having a long-standing illness, indicating a substantial and growing chronic disease burden. The OECD further notes that 82% of primary care users aged 45 and older reported at least one chronic condition in 2024, with 52% experiencing two or more conditions, emphasizing the increasing prevalence of chronic diseases and the rising need for effective long-term healthcare management.

mRNA Vaccines And Therapeutics Market- Segmentation Analysis:

The Global mRNA Vaccines And Therapeutics Market is segmented on the basis of Treatment Type, Type, Application, End User, and Region.

The market is divided into three categories based on treatment type: monoclonal antibody, gene therapy, and cell therapy. The monoclonal antibody segment accounts for a significant portion of the market due to its effectiveness in targeted disease treatment. Targeted disease treatment refers to therapeutic approaches designed to specifically identify and act on particular cells, proteins, or pathways associated with a disease. This method enhances treatment precision, improves clinical outcomes, and minimizes damage to healthy cells. In the context of mRNA Vaccines And Therapeutics, monoclonal antibodies are widely used to support immune-based therapies for conditions such as cancer, infectious diseases, and autoimmune disorders. These treatments help neutralize harmful pathogens, block disease-causing mechanisms, and strengthen immune responses, contributing to more effective and advanced therapeutic solutions. For instance, in February 2025, according to the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), biologic medicines including monoclonal antibodies already benefit more than 350 million patients globally for the treatment of diseases such as cancer, diabetes, and rare disorders. The report also highlights the continued expansion of pharmaceutical innovation, with 69 novel active substances launched globally in 2023 and over 12,700 medicines in different phases of clinical development as of October 2024, reflecting strong growth in advanced biologic and antibody-based therapies.

The market is divided into two categories based on type: self-amplifying mRNA-based vaccines and conventional non-amplifying mRNA-based vaccines. The Self-Amplifying mRNA-Based Vaccines segment accounts for a significant portion of the market due to its enhanced protein expression and dose-sparing potential. Enhanced protein expression refers to the ability of self-amplifying mRNA vaccines to replicate their RNA within cells, producing higher levels of antigen and eliciting stronger immune responses. In self-amplifying mRNA-based vaccines, this increased expression allows for broader immune coverage, potentially fewer booster doses, and faster response to emerging pathogens. These advantages make self-amplifying mRNA vaccines highly attractive for applications in infectious diseases, oncology, and personalized therapeutics, supporting the rapid growth and adoption of mRNA vaccine technologies globally. For instance, in January 2026, according to the UK Government Medicines and Healthcare Products Regulatory Agency, Zapomeran (Kostaive), a self-amplifying mRNA COVID-19 vaccine for adults aged 18 years and older in the UK, was approved, marking one of the first regulatory authorizations of an sa-mRNA vaccine and highlighting a shift toward next-generation mRNA technology in public health responses, with the vaccine administered as a single 0.5 mL booster dose containing self-amplifying messenger RNA designed to help the body make the SARS-CoV-2 spike protein and strengthen immunity against COVID-19.

mRNA Vaccines And Therapeutics Market- Geographical Insights

The mRNA Vaccines And Therapeutics Market exhibits clear regional variation, shaped by differences in healthcare infrastructure, R&D investment, and technology adoption. North America shows growing adoption of mRNA-based therapies, widespread clinical trials, and increasing focus on personalized medicine, particularly in the U.S. and Canada. Europe demonstrates consistent growth, driven by rising investments in biotechnology, supportive regulatory frameworks, and the adoption of innovative vaccine platforms. Asia Pacific is expanding rapidly, fueled by rising healthcare access, large patient populations, increasing government support, and the development of local biotechnology capabilities in countries such as China, India, Japan, and South Korea. In contrast, Latin America, the Middle East, and Africa are developing their market presence, supported by improving healthcare infrastructure, growing awareness of mRNA therapeutics, and increasing participation in clinical research and vaccine programs.

Japan mRNA Vaccines And Therapeutics Market - Country Insights

The Japan mRNA Vaccines And Therapeutics market is experiencing consistent growth, driven by a well-developed healthcare infrastructure and rapid adoption of biotechnology innovations. Healthcare providers and research institutions are increasingly utilizing mRNA Vaccines And Therapeutics to prevent infectious diseases and support personalized medicine initiatives. Strong participation from leading domestic and global pharmaceutical companies, along with supportive government policies for vaccine development and approval, continues to encourage market expansion. Additionally, growing emphasis on improving public health outcomes and advancing immunization programs is further accelerating adoption across healthcare and research settings in Japan. For instance, in 2025, according to the Commonwealth Fund's organization, Japan's statutory health insurance system covers about 98.3% of the population, ensuring nearly universal access to hospital care, primary and specialty services, and prescription drugs under mandatory residence- and employment-based plans; the national government sets the health insurance fee schedule and subsidizes local governments and insurers to maintain quality and affordability, while out-of-pocket maximums range from JPY 340,000 to 2.12 million annually (USD 3,400-21,200) depending on age and income, demonstrating sustained government policy support for comprehensive healthcare coverage and financial protection.

mRNA Vaccines And Therapeutics Market- Competitive Landscape:

The mRNA Vaccines And Therapeutics Market is moderately concentrated, with several leading biotechnology and pharmaceutical companies driving competition. Key players include Pfizer Inc., Moderna, Inc., BioNTech SE, GlaxoSmithKline, Daiichi Sankyo, CureVac N.V., AstraZeneca, Ethris, Sanofi, Arcturus Therapeutics, Innovac Therapeutics, Kernal Biologics, Pantherna Therapeutics, pHion Therapeutics, Recode Therapeutics, Rejuvenation Technologies, RNAimmune, Strand Therapeutics, Walvax, and Ziphius Vaccines. These companies compete by developing innovative mRNA-based vaccines and therapeutics for infectious diseases, oncology, and personalized medicine. For example, in 2024, Moderna, Inc. advanced its mRNA vaccine platform to include self-amplifying mRNA technology, enabling enhanced protein expression, improved immune responses, and faster adaptation to emerging pathogens. The market is driven by increasing demand for effective, rapid-response vaccines and therapeutics, particularly in the context of emerging infectious diseases and cancer immunotherapy. Additionally, companies are expanding capabilities with enhanced delivery systems, multi-dose formulations, predictive immunogenicity modeling, and scalable manufacturing platforms to meet the evolving needs of healthcare systems and the growing preference for innovative, accessible, and safe mRNA-based treatments.

Recent Developments:

In 2025, Pfizer Inc. announced a collaboration with a leading biotechnology partner to develop next-generation mRNA vaccines aimed at improving immune response, expanding protection against emerging infectious diseases, and enhancing vaccine delivery efficiency. This initiative demonstrates Pfizer's commitment to leveraging cutting-edge mRNA technology to advance global health, potentially establishing a new standard in vaccine innovation. The partnership is set to utilize self-amplifying mRNA and enhanced delivery platforms, positioning Pfizer as a leader in innovative mRNA therapeutics.

In 2024, Kernal Biologics initiated a joint project with a prominent research institute to develop advanced mRNA therapeutics for oncology and personalized medicine applications. The collaboration focuses on optimizing mRNA design, delivery systems, and immunogenicity to improve patient outcomes. By integrating scalable manufacturing processes and predictive modeling, Kernal Biologics aims to strengthen its position as a key innovator in next-generation mRNA-based therapies.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL MRNA VACCINES AND THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

AstraZeneca
Arcturus Therapeutics
BioNTech SE
CureVac N.V.
Daiichi Sankyo
Ethris
GlaxoSmithKline
Innovac Therapeutics
Kernal Biologics
Pantherna Therapeutics
pHion Therapeutics
Pfizer Inc.
Recode Therapeutics
Rejuvenation Technologies
RNAimmune
Strand Therapeutics
Moderna, Inc.
Walvax
Ziphius Vaccines
Others

GLOBALMRNA VACCINES AND THERAPEUTICS MARKET, BY TREATMENT TYPE - MARKET ANALYSIS, 2020 - 2033

Cell Therapy
Gene Therapy
Monoclonal Antibody
Other

GLOBAL MRNA VACCINES AND THERAPEUTICS MARKET, BY TYPE - MARKET ANALYSIS, 2020 - 2033

Conventional Non-Amplifying mRNA-Based Vaccines
Self-Amplifying mRNA-based Vaccines

GLOBAL MRNA VACCINES AND THERAPEUTICS MARKET, BY APPLICATION- MARKET ANALYSIS, 2020 - 2033

Autoimmune Diseases
Cancer
Infectious Diseases
Others

GLOBAL MRNA VACCINES AND THERAPEUTICS MARKET, BY END USER- MARKET ANALYSIS, 2020 - 2033

Clinics
Hospitals
Research Laboratories and Organizations
Others

GLOBAL MRNA VACCINES AND THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA

Product Code: ANV6180

1. mRNA Vaccines And Therapeutics Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. mRNA Vaccines And Therapeutics Market Snippet by Treatment Type
- 2.1.2. mRNA Vaccines And Therapeutics Market Snippet by Type
- 2.1.3. mRNA Vaccines And Therapeutics Market Snippet by Application
- 2.1.4. mRNA Vaccines And Therapeutics Market Snippet by End User
- 2.1.5. mRNA Vaccines And Therapeutics Market Snippet by Country
- 2.1.6. mRNA Vaccines And Therapeutics Market Snippet by Region
2.2. Competitive Insights

3. mRNA Vaccines And Therapeutics Key Market Trends

3.1. mRNA Vaccines And Therapeutics Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. mRNA Vaccines And Therapeutics Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. mRNA Vaccines And Therapeutics Market Opportunities
3.4. mRNA Vaccines And Therapeutics Market Future Trends

4. mRNA Vaccines And Therapeutics Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. mRNA Vaccines And Therapeutics Market: Impact of Escalating Geopolitical Tensions

5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts

6. mRNA Vaccines And Therapeutics Market Landscape

6.1. mRNA Vaccines And Therapeutics Market Share Analysis, 2025
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. mRNA Vaccines And Therapeutics Market - By Treatment Type

7.1. Overview
- 7.1.1. Segment Share Analysis, By Treatment Type, 2025&2033 (%)
- 7.1.2. Cell Therapy
- 7.1.3. Gene Therapy
- 7.1.4. Monoclonal Antibody
- 7.1.5. Other

8. mRNA Vaccines And Therapeutics Market - By Type

8.1. Overview
- 8.1.1. Segment Share Analysis, By Type, 2025&2033 (%)
- 8.1.2. Conventional Non-Amplifying mRNA-Based Vaccines
- 8.1.3. Self-Amplifying mRNA-based Vaccines

9. mRNA Vaccines And Therapeutics Market - By Application

9.1. Overview
- 9.1.1. Segment Share Analysis, By Application, 2025&2033 (%)
- 9.1.2. Autoimmune Diseases
- 9.1.3. Cancer
- 9.1.4. Infectious Diseases
- 9.1.5. Others

10. mRNA Vaccines And Therapeutics Market - By End User

10.1. Overview
- 10.1.1. Segment Share Analysis, By Type, 2025&2033 (%)
- 10.1.2. Clinics
- 10.1.3. Hospitals
- 10.1.4. Research Laboratories and Organizations
- 10.1.5. Others

11. mRNA Vaccines And Therapeutics Market- By Geography

11.1. Introduction
- 11.1.1. Segment Share Analysis, By Geography, 2025&2033 (%)
11.2. North America
- 11.2.1. Overview
- 11.2.2. mRNA Vaccines And Therapeutics Key Manufacturers in North America
- 11.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 11.2.4. North America Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.2.5. North America Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 11.2.6. North America Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 11.2.7. North America Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.2.8. U.S.
  - 11.2.8.1. Overview
  - 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.2.8.3. U.S. Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.2.8.4. U.S. Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.2.8.5. U.S. Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 11.2.8.6. U.S. Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.2.9. Canada
  - 11.2.9.1. Overview
  - 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.2.9.3. Canada Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.2.9.4. Canada Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.2.9.5. Canada Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 11.2.9.6. Canada Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.3. Europe
- 11.3.1. Overview
- 11.3.2. mRNA Vaccines And Therapeutics Key Manufacturers in Europe
- 11.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 11.3.4. Europe Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.3.5. Europe Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 11.3.6. Europe Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 11.3.7. Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.3.8. Germany
  - 11.3.8.1. Overview
  - 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.8.3. Germany Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.3.8.4. Germany Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.3.8.5. Germany Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 11.3.8.6. Germany Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.3.9. UK
  - 11.3.9.1. Overview
  - 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.9.3. UK Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.3.9.4. UK Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.3.9.5. UK Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 11.3.9.6. UK Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.3.10. France
  - 11.3.10.1. Overview
  - 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.10.3. France Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.3.10.4. France Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.3.10.5. France Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 11.3.10.6. France Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.3.11. Italy
  - 11.3.11.1. Overview
  - 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.11.3. Italy Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.3.11.4. Italy Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.3.11.5. Italy Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 11.3.11.6. Italy Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.3.12. Spain
  - 11.3.12.1. Overview
  - 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.12.3. Spain Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.3.12.4. Spain Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.3.12.5. Spain Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 11.3.12.6. Spain Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.3.13. The Netherlands
  - 11.3.13.1. Overview
  - 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.13.3. The Netherlands Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.3.13.4. The Netherlands Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.3.13.5. The Netherlands Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 11.3.13.6. The Netherlands Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.3.14. Sweden
  - 11.3.14.1. Overview
  - 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.14.3. Sweden Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.3.14.4. Sweden Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.3.14.5. Sweden Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 11.3.14.6. Sweden Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.3.15. Russia
  - 11.3.15.1. Overview
  - 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.15.3. Russia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.3.15.4. Russia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.3.15.5. Russia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 11.3.15.6. Russia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.3.16. Poland
  - 11.3.16.1. Overview
  - 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.16.3. Poland Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.3.16.4. Poland Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.3.16.5. Poland Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 11.3.16.6. Poland Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.3.17. Rest of Europe
  - 11.3.17.1. Overview
  - 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.17.3. Rest of the Europe Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.3.17.4. Rest of the Europe Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.3.17.5. Rest of the Europe Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 11.3.17.6. Rest of the Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.4. Asia Pacific (APAC)
- 11.4.1. Overview
- 11.4.2. mRNA Vaccines And Therapeutics Key Manufacturers in Asia Pacific
- 11.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 11.4.4. APAC Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.4.5. APAC Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 11.4.6. APAC Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 11.4.7. APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.4.8. China
  - 11.4.8.1. Overview
  - 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.4.8.3. China Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.4.8.4. China Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.4.8.5. China Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 11.4.8.6. China Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.4.9. India
  - 11.4.9.1. Overview
  - 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.4.9.3. India Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.4.9.4. India Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.4.9.5. India Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 11.4.9.6. India Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.4.10. Japan
  - 11.4.10.1. Overview
  - 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.4.10.3. Japan Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.4.10.4. Japan Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.4.10.5. Japan Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 11.4.10.6. Japan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.4.11. South Korea
  - 11.4.11.1. Overview
  - 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.4.11.3. South Korea Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.4.11.4. South Korea Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.4.11.5. South Korea Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 11.4.11.6. South Korea Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.4.12. Australia
  - 11.4.12.1. Overview
  - 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.4.12.3. Australia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.4.12.4. Australia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.4.12.5. Australia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 11.4.12.6. Australia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.4.13. Indonesia
  - 11.4.13.1. Overview
  - 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.4.13.3. Indonesia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.4.13.4. Indonesia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.4.13.5. Indonesia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 11.4.13.6. Indonesia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.4.14. Thailand
  - 11.4.14.1. Overview
  - 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.4.14.3. Thailand Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.4.14.4. Thailand Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.4.14.5. Thailand Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 11.4.14.6. Thailand Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.4.15. Philippines
  - 11.4.15.1. Overview
  - 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.4.15.3. Philippines Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.4.15.4. Philippines Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.4.15.5. Philippines Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 11.4.15.6. Philippines Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.4.16. Rest of APAC
  - 11.4.16.1. Overview
  - 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.4.16.3. Rest of APAC Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.4.16.4. Rest of APAC Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.4.16.5. Rest of APAC Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 11.4.16.6. Rest of APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.5. Latin America (LATAM)
- 11.5.1. Overview
- 11.5.2. mRNA Vaccines And Therapeutics Key Manufacturers in Latin America
- 11.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 11.5.4. LATAMMarket Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.5.5. LATAMMarket Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 11.5.6. LATAMMarket Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 11.5.7. LATAMMarket Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.5.8. Brazil
  - 11.5.8.1. Overview
  - 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.5.8.3. Brazil Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.5.8.4. Brazil Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.5.8.5. Brazil Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 11.5.8.6. Brazil Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.5.9. Mexico
  - 11.5.9.1. Overview
  - 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.5.9.3. Mexico Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.5.9.4. Mexico Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.5.9.5. Mexico Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 11.5.9.6. Mexico Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.5.10. Argentina
  - 11.5.10.1. Overview
  - 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.5.10.3. Argentina Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.5.10.4. Argentina Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.5.10.5. Argentina Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 11.5.10.6. Argentina Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.5.11. Colombia
  - 11.5.11.1. Overview
  - 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.5.11.3. Colombia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.5.11.4. Colombia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.5.11.5. Colombia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 11.5.11.6. Colombia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.5.12. Rest of LATAM
  - 11.5.12.1. Overview
  - 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.5.12.3. Rest of LATAM Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.5.12.4. Rest of LATAM Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.5.12.5. Rest of LATAM Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 11.5.12.6. Rest of LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.6. Middle East and Africa (MEA)
- 11.6.1. Overview
- 11.6.2. mRNA Vaccines And Therapeutics Key Manufacturers in Middle East and Africa
- 11.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 11.6.4. MEA Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.6.5. MEA Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 11.6.6. MEA Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 11.6.7. MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.6.8. Saudi Arabia
  - 11.6.8.1. Overview
  - 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.6.8.3. Saudi Arabia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.6.8.4. Saudi Arabia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.6.8.5. Saudi Arabia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 11.6.8.6. Saudi Arabia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.6.9. United Arab Emirates
  - 11.6.9.1. Overview
  - 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.6.9.3. United Arab Emirates Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.6.9.4. United Arab Emirates Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.6.9.5. United Arab Emirates Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 11.6.9.6. United Arab Emirates Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.6.10. Israel
  - 11.6.10.1. Overview
  - 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.6.10.3. Israel Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.6.10.4. Israel Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.6.10.5. Israel Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 11.6.10.6. Israel Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.6.11. Turkey
  - 11.6.11.1. Overview
  - 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.6.11.3. Turkey Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.6.11.4. Turkey Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.6.11.5. Turkey Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 11.6.11.6. Turkey Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.6.12. Algeria
  - 11.6.12.1. Overview
  - 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.6.12.3. Algeria Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.6.12.4. Algeria Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.6.12.5. Algeria Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 11.6.12.6. Algeria Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.6.13. Egypt
  - 11.6.13.1. Overview
  - 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.6.13.3. Egypt Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.6.13.4. Egypt Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.6.13.5. Egypt Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 11.6.13.6. Egypt Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.6.14. Rest of MEA
  - 11.6.14.1. Overview
  - 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.6.14.3. Rest of MEA Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.6.14.4. Rest of MEA Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.6.14.5. Rest of MEA Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 11.6.14.6. Rest of MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)

12. Key Vendor Analysis- mRNA Vaccines And Therapeutics Industry

12.1. Competitive Benchmarking
- 12.1.1. Competitive Dashboard
- 12.1.2. Competitive Positioning
12.2. Company Profiles
- 12.2.1. AstraZeneca
- 12.2.2. Arcturus Therapeutics
- 12.2.3. BioNTech SE
- 12.2.4. CureVac N.V.
- 12.2.5. Daiichi Sankyo
- 12.2.6. Ethris
- 12.2.7. GlaxoSmithKline
- 12.2.8. Innovac Therapeutics
- 12.2.9. Kernal Biologics
- 12.2.10. Pantherna Therapeutics
- 12.2.11. pHion Therapeutics
- 12.2.12. Pfizer Inc.
- 12.2.13. Recode Therapeutics
- 12.2.14. Rejuvenation Technologies
- 12.2.15. RNAimmune
- 12.2.16. Strand Therapeutics
- 12.2.17. Moderna, Inc.
- 12.2.18. Walvax
- 12.2.19. Ziphius Vaccines
- 12.2.20. Others

13. 360 Degree AnalystView

14. Appendix

14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us